Perspectives on U.S. Diagnostics Commercialization

The route-to-market decision is one of the most expensive a diagnostics company makes in a U.S. launch — and one of the most frequently made on instinct rather than evidence.

A direct sales force gives a company control over the customer relationship, messaging, and feedback loop. It also requires sustained capital, a hiring plan, and management depth that many international companies underestimate when entering the U.S. A distribution model extends reach faster and with less fixed cost, but it hands the customer relationship to a partner whose priorities may not align with the company's, and whose portfolio may place the product alongside competing options.

A hybrid model — direct in priority accounts, distribution in secondary geographies — is often the right answer for diagnostics, but only when the company can define which accounts are priority, why, and how the two channels coexist without conflict. Without that definition, hybrid becomes an excuse for avoiding the decision.

The right route to market depends on the product's economics, the customer's buying behavior, the company's capital position, and the competitive landscape. It is a commercial decision, not a logistical one — and it should be tested against the company's commercial readiness before the first sales hire is made.

In diagnostics, reimbursement is not a back-office detail. It is a commercial gate.

A test without a clear reimbursement pathway forces the customer to absorb the cost, fight for coverage case by case, or limit ordering to research budgets. Each of those outcomes suppresses utilization. A strong clinical profile does not overcome a weak reimbursement position — it simply makes the gap more frustrating for everyone involved.

U.S. reimbursement for diagnostics is shaped by Medicare coverage policies, private payer adoption, laboratory developed test frameworks, and site-of-care economics. A test that is economically attractive in a reference laboratory setting may be unworkable in a hospital or point-of-care environment where the cost structure and decision-maker are different. Pricing that assumes one setting can fail in another.

Reimbursement planning belongs at the start of commercialization, alongside customer segmentation and pricing — not after the product is built and the channel is selected. When a company understands the reimbursement pathway early, it can shape the evidence package, the pricing model, and the target customer around a path that actually pays. When it treats reimbursement as a downstream problem, the company usually discovers the gap after the commercial model is already locked in.

Diagnostics companies routinely enter U.S. market planning with a top-down market size figure. The figure is usually correct, and usually insufficient.

Market size describes how many tests could theoretically be performed. It says nothing about who pays, how much they pay, what they must invest to adopt the platform, or how often the test will actually be ordered once the platform is in place. A billion-dollar market that requires a customer to disrupt an established workflow, accept a lower margin, or commit capital upfront is not a billion-dollar opportunity — it is a hypothesis.

Commercial strategy begins where market sizing ends. It asks whether the customer can economically justify adoption, whether the reimbursement pathway supports the price, whether the usage frequency sustains a recurring model, and whether the channel can reach the accounts that matter. A credible U.S. plan answers those questions before the company builds infrastructure around an assumption.

The companies that enter the U.S. market successfully are rarely the ones with the largest market size estimate. They are the ones that understood, before committing capital, which slice of that market was actually reachable — and built a commercial model around that slice.